EGFR and lung adenocarcinoma: There is an ongoing trial of comparing upfront erlotinib with WBRT at initial presentation to erlotinib alone with WBRT at disease progression in patients with EGFR-mutant lung adenocarcinoma with BM (clinicaltrials.gov ID NCT01763385), with mature data pending.